Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1063-1070

  Tripathy, Debu ^a   Slamon, Dennis J ^a   Cobleigh, Melody ^a   Arnold, Andrew ^a   Saleh, Mansoor ^a   Mortimer, Joanne E ^a   Murphy, Maureen ^a   Stewart, Stanford J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER GROWTH; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PALLIATIVE THERAPY; PRIORITY JOURNAL; BREAST TUMOR; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; PATHOLOGY; SAFETY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; RECEPTOR, ERBB-2; SAFETY;

EID: 1842614245     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.557     Document Type: Article

References (14)

1. Kallioniemi OP, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321-5325, 1992
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
4. Ross JS, Fletcher JA, Linette GP, et al: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307-325, 2003
5. Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446, 2000
6. Izumi Y, Xu L, di Tomaso E, et al: Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280, 2002
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
8. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
9. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
10. Tripathy D, Seidman A, Hudis C, et al: Effect of cardiac dysfunction of treatment outcome in the Herceptin (trastuzumab) pivotal trial. Proc Am Soc Clin Oncol 20:49a, 2001 (abstr 191)
11. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
12. Gelmon K, Mackey J, Verma S, et al: Efficacy and safety of Herceptin in women with HER2-positive metastatic breast cancer who have progressed on a prior Herceptin-containing regimen. Breast Cancer Res Treat 76:S113, 2002 (suppl 1; abstr 440)
13. Fountzilas G, Razis E, Tsavdaridis D, et al: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: A retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 4:120-125, 2003
14. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999